iRadimed (IRMD) Projected to Announce Quarterly Earnings on Thursday

iRadimed (NASDAQ:IRMD) is expected to be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect iRadimed to post earnings of $0.44 per share and revenue of $20.35 million for the quarter. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, July 31, 2026 at 11:00 AM ET.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The firm had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million.

iRadimed Price Performance

Shares of iRadimed stock opened at $94.08 on Thursday. The stock has a market capitalization of $1.20 billion, a P/E ratio of 51.41 and a beta of 0.90. The business has a 50 day simple moving average of $93.86 and a two-hundred day simple moving average of $95.88. iRadimed has a 12 month low of $55.11 and a 12 month high of $107.90.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were given a $0.20 dividend. The ex-dividend date was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is 43.72%.

Analyst Ratings Changes

Several equities analysts have weighed in on IRMD shares. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $120.00.

Insider Buying and Selling at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $87.51, for a total value of $437,550.00. Following the completion of the transaction, the chief executive officer owned 2,175,000 shares of the company’s stock, valued at $190,334,250. This trade represents a 0.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,000 shares of company stock valued at $2,170,753 in the last ninety days. Insiders own 34.60% of the company’s stock.

Institutional Investors Weigh In On iRadimed

A number of large investors have recently modified their holdings of IRMD. Quarry LP purchased a new position in iRadimed in the third quarter valued at $40,000. Tower Research Capital LLC TRC lifted its holdings in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the last quarter. Virtus Advisers LLC acquired a new position in shares of iRadimed during the 3rd quarter worth about $117,000. Aquatic Capital Management LLC increased its holdings in shares of iRadimed by 210,400.0% in the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock valued at $150,000 after acquiring an additional 2,104 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of iRadimed in the 4th quarter valued at about $218,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.